Nakashima, Kazuhisa
Ozawa, Yuichi
Daga, Haruko
Imai, Hisao
Tamiya, Motohiro
Tokito, Takaaki
Kawamura, Takahisa
Akamatsu, Hiroaki
Tsuboguchi, Yuko
Takahashi, Toshiaki
Yamamoto, Nobuyuki
Mori, Keita
Murakami, Haruyasu
Article History
Received: 26 March 2020
Accepted: 29 April 2020
First Online: 18 May 2020
Compliance with ethical standards
:
: Kazuhisa Nakashima declares that he has no conflict of interest. Yuichi Ozawa had received personal fees from AstraZeneca, Boehringer Ingelheim, and Chugai Pharma. Haruko Daga had received personal fees from Boehringer Ingelheim, Chugai Pharma, and Ono Pharmaceutical, and grants from Astella, Pfizer, and Taiho Pharmaceutical. Hisao Imai declares that he has no conflict of interest. Motohiro Tamiya had received personal fees from Asahi Kasei Pharmaceutical, AstraZeneca, Chugai Pharma, Eli Lilly, MSD, and Taiho Pharmaceutical, and personal fees and grants from Boehringer Ingelheim, Bristol-Myers Squibb, and Ono Pharmaceutical. Takaaki Tokito had received personal fees from AstraZeneca, Boehringer Ingelheim, and Chugai Pharma. Takahisa Kawamura declares that he has no conflict of interest. Hiroaki Akamatsu had received personal fees from AstraZeneca, Boehringer Ingelheim, Chugai Pharma, and Pfizer. Yuko Tsuboguchi declares that he has no conflict of interest. Toshiaki Takahashi had received personal fees from Boehringer Ingelheim and Roche Diagnostics K.K., grants from Japan Agency for Medical Research and Development, and personal fees and grants from AstraZeneca, Chugai Pharma, Eli Lilly, MSD, Ono Pharmaceutical, and Pfizer. Nobuyuki Yamamoto had received personal fees from AstraZeneca, and personal fees and grants from Boehringer Ingelheim and Chugai Pharma. Keita Mori declares that he has no conflict of interest. Haruyasu Murakami had received personal fees from Bristol-Myers Squibb, Ono Pharmaceutical, and MSD, grants from Abbvie, Daiichi Sankyo, and IQvia, and personal fees and grants from AstraZeneca, Chugai Pharma, Eli Lilly, Taiho Pharmaceutical, and Takeda.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and the 1964 Helsinki declaration and its later amendments or with comparable ethical standards. This trial was registered with the Japan Registry of Clinical Trials on March 12, 2019 (trial no. jRCT1041180081).
: Informed consent was obtained from all individual participants included in the study.